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LETTERS
Unmasked tuberculosis or lymphoma in late AIDS
presenters: a difficult differential diagnosis
To the Editors:
Despite dramatic progress in the management of HIV infection
[1], late presentation remains a major threat to survival [2].
Difficult diagnosis of AIDS-related illnesses could pose
additional challenge. Tuberculosis (TB) is considered to be
the most frequent opportunistic infection worldwide. Smear-
negative pulmonary TB or extrapulmonary TB diagnosis may
be difficult to rule out, either because of inadequate laboratory
markers, or overlapping clinical presentation with other
conditions, such as lymphoproliferative disorders. In addition,
in the era of combination antiretroviral therapy (cART),
unmasked TB could develop as immune reconstitution
inflammatory syndrome (IRIS) after cART is commenced in
treatment-naı¨ve subjects with advanced HIV infection. Here
we describe two cases of AIDS-related diseases, with similar
presentation but different diagnosis and outcome.
The first patient was a 37-yr-old male, who was born in Togo
and had lived in Italy for 2 yrs, presented to our attention in
May 2008 for mild fever and chest pain. He had been
diagnosed for the first time with pulmonary TB (acid-fast
bacilli in the sputum smear) and advanced HIV infection
(CD4+ T-cell count 40 cells?mm-3) 2 months earlier, elsewhere.
The patient had been treated for 2 months with rifampin,
isoniazid, ethambutol and pyrazinamide, but had not started
cART. On admission, physical examination showed enlarge-
ment of the liver, but no superficial lymphadenopathy.
Laboratory tests showed mild anaemia (haemoglobin
11.7 g?dL-1, mean corpuscolar volume 75.9 fL), normal white
blood cells and platelet count, and increased erythrocyte
sedimentation rate (72 mm?h-1) and levels of serum lactate
dehydrogenase (LDH) (1,173 IU?L-1). Chest radiography
revealed bilateral perihilar and lower right lung infiltrates.
Sputum smear did not reveal the presence of acid-fast bacilli. A
computed tomography (CT) scan of chest and abdomen
showed an abdominal mass of 1066 cm in the pelvis and
thickening of ileum wall, while nuclear magnetic resonance of
the brain was normal. These findings were considered
indicative of abdominal TB and a transcutaneous biopsy was
not performed because of the risk of intestinal perforation.
Mycobacterium antibiogram was not available at that time;
therefore, a multidrug resistant TB could not be excluded.
Moreover, a paradoxical worsening of clinical conditions even
in the absence of cART has been previously reported as a form
of IRIS, which was, therefore, considered in the differential
diagnosis. Corticosteroid treatment was not prescribed owing
to the uncertainty of diagnosis in the current stable patient’s
conditions. After 2 weeks, clinical conditions progressively
deteriorated: haemoglobin dropped to 8 g?dL-1, LDH increased
to 3,126 IU?L-1, pulmonary infiltrates expanded, breathing rate
increased to 40 breaths?min-1, compensating arterial hypoxae-
mia. Pending bronchoscopy results, empirical therapy with
cotrimoxazole against suspected pulmonary pneumocystosis
and large-spectrum antibiotic treatment with piperacilline/
tazobactam did not lead to clinical improvement. Sputum,
urine and stool smears were negative for acid-fast bacilli, thus
supporting the hypothesis of IRIS. TB susceptibility test of the
originally isolated strain became available, showing full
sensitivity to the ongoing therapy, which was therefore
confirmed. Thereafter, the patient developed left eye
exophthalmos, and CT scan revealed a retro-orbitary mass. A
transnasal biopsy led to the diagnosis of B-cell lymphoma.
Bone marrow biopsy was performed for staging, and char-
acterised the malignancy as a Burkitt’s lymphoma.
Unfortunately, diagnosis arrived too late; the patient died of
septic shock, possibly secondary to intestinal perforation.
The second patient was a 59-yr-old, HIV-infected male, born in
Angola and living in Italy, who had started first-line cART
with zidovudine, lamivudine and nevirapine 6 months earlier
(nadir CD4+ T-cell count 21 cells?mm-3). He presented with
fever (39.5uC), weight loss and pancytopenia. At that time, his
CD4+ T-cell count was 65 cells?mm-3 and viral load was
undetectable. Complete blood cell count showed: white blood
cells 210 cells?mm-3, red blood cells 1,620,000 cells?mm-3,
haemoglobin 5.1 g?dL-1 and platelets 104,000 cells?mm-3. The
severe and rapid-onset pancytopenia led diagnostic suspicion
towards haematological malignancies, and a bone marrow
biopsy revealed a monocyte-macrophage activation syndrome,
strongly supporting the suspect of lymphoproliferative disease.
Chest radiograph showed micronodular infiltrates. Repeated
sputum, bronchoalveolar lavage, urine and peripheral blood
examinations were negative, while only a direct stool smear test
revealed few acid-fast bacilli. Although the clinical TB presenta-
tion was actually atypical, anti-mycobacterial treatment with
rifampin, isoniazid, ethambutol and pyrazinamide was started
and progressively led to clinical amelioration, with rapid
resolution of pancytopenia. Eventually, after 8 weeks of incuba-
tion, Mycobacterium tuberculosis was isolated from blood cultures
of bone marrow aspirate, confirming the diagnosis of unmasked
TB presentation.
Late presentation of advanced HIV infection still has high
mortality, which is driven either by the severity of AIDS-related
disease or by the consequences of IRIS and unmasked TB. In this
context, timely cART initiation becomes a critical issue.
In this report, both patients originated from African countries
with high TB prevalence, and both presented with advanced
HIV infection, haematological abnormalities and underlying
mycobacterial disease.
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In the first case, the fear of IRIS led to a delay in cART
initiation. Despite the fact that IRIS can lead to a paradoxical
exacerbation of the clinical status, a diagnosis of TB should not
prevent cART introduction in patients with advanced HIV
infection. Previous studies have suggested that simultaneous
use of cART and anti-TB treatment in patients with CD4+ T-
cell counts ,200 cells?mm-3 could have a significant impact on
survival [3, 4]. Moreover, a recent randomised trial demon-
strated that, at least in resource-limited settings, cART also has
the potential to reduce mortality in patients with relatively
conserved immune function (i.e. CD4+ T-cell counts 200–
500 cells?mm-3) [5].
Worsening of the patient’s symptoms were initially attributed
to TB progression or to IRIS, which can sometimes occur after
specific treatment initiation, even in the absence of antiretro-
viral therapy [6]. Nonetheless, concomitant opportunistic
infections are likely in HIV-infected patients, particularly
when CD4+ T-cell count is low, and should always be ruled
out when anti-mycobacterial treatment fails to improve the
patient’s conditions. In these circumstances, a more rapid and
aggressive diagnostic work-up could have substantially
improved the patient’s outcome.
While in the first patient the symptoms were not immediately
suggestive of lymphoma because of the concurrent pulmonary
TB, in the second patient, who presented with a more evident
haematological impairment, the haemophagocytic syndrome
was probably an expression of IRIS, that unmasked dissemi-
nated TB [7]. It is plausible that concurrent TB and HIV
infection contributed to the development of haemophagocytic
syndrome, whose mortality rate greatly depends on timely
diagnosis and treatment of the underlying condition [8].
In the western world HIV mortality has dramatically decreased
with the introduction of cART, but HIV patients still die when
late HIV diagnosis combines with severe opportunistic diseases
or HIV-related malignancies. Globalisation and migration from
poor-income to high-income countries have contributed to
raising the latent and overt TB burden in industrialised
countries, resulting in the need for improving disease control
strategies. Thus, a special effort, particularly in patients with
advanced HIV infection who are coming from endemic TB
areas, such as sub-Saharan African countries, should be made to
screen for underlying TB, in order to prevent severe unmasking
forms of the disease. Therefore, we would suggest that acid-fast
bacilli are thoroughly sought for in biological fluids such as
sputum, blood, urine and stools in patients with CD4+ T cell
counts ,200 cells?mm-3. Moreover, new tools in TB diagnostics,
such as molecular biology essays (PCR and in situ hybridisation
by specific probe) could offer a great advantage in this task, but
there is still a need of a novel rapid diagnostic technology which
allows to discriminate between latent and disseminated active
TB infections [9].
These two case reports represent two unusual presentation of
AIDS-defining illnesses in which the complex interplay and
mutual masking between an underlying opportunistic infec-
tion and host immune–haematological response could render
the differential diagnosis a critical task for the clinician.
Aggressive diagnostic and treatment efforts should be engaged
to achieve possible recovery of these severe syndromes [10].
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